Azithromycin in labour to reduce maternal and newborn sepsis and associated deaths: the need for a harmonized approach

Gates Open Research

article

Elizabeth M. McClure¹  Anna Roca²  Karen Kotloff³  Waldemar A. Carlo⁴  Umberto D²  Halidou Tinto⁵  Bully Camara²  Elwyn Chomba⁶  Samba O. Sow⁷  Amanda Driscoll²  Jennifer Hemingway-Foday¹  Alan Tita⁴ 

[1] RTI International;Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine;Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine;University of Alabama at Birmingham;Institut de Recherche en Sciences de la Santé;University Teaching Hospital;Centre pour le Développement des Vaccins

关键词: stillbirth;    MITS;    azithromycin;    pathology;   

DOI  :  10.12688/gatesopenres.14214.1

学科分类：电子与电气工程

来源: American Journal Of Pharmtech Research

【 摘 要 】

Maternal and newborn infections are a major contributor to mortality and morbidity globally.  Lost-cost, effective and safe interventions are needed to address these.  Based on promising findings, azithromycin has been identified as potentially effective antibiotic to reduce maternal and newborn infections in low- and middle-income countries (LMICs).  However, robust randomized clinical trials in a range of settings are needed to confirm these findings as well as to understand the implications for antimicrobial resistance.  To better understand the impact of azithromycin on maternal and newborn health, at least three clinical trials are being conducted to evaluate azithromycin in LMICs.  We describe these trials, the importance of harmonizing study measures and the potential public health impact of azithromycin in LMICs.

【 授权许可】

CC BY